About the role
About Eucalyptus We're on a mission to make good health last a lifetime. More than 1 billion people live with obesity worldwide, driving preventable chronic conditions. We're here to build better long-term care. Eucalyptus is now part of Hims & Hers, the global leader in personalised health and wellness. Euc is the company behind Juniper, one of the world's largest weight-management programs combining GLP-1 medication with personalised nutrition, movement support, and clinician-led care from prescribers, nurses, health coaches, pharmacists, and dietitians. Our published clinical research shows that our combined clinical and behavioural approach helps patients lose significantly more weight during their treatment with Juniper by four times. Our Growth Story: Supporting patients living with obesity across our 5 markets Received selective NICE endorsement to provide services to the NHS Tailored our offering to thousands of patients in Australia, the UK, Germany, Japan and Canada. About Euc We’re making good health last life a lifetime More than 1 billion people globally live with obesity — a major leading indicator of many preventable chronic diseases such as diabetes and heart disease. Eucalyptus is the company behind “Juniper”, one of the world’s largest weight management programs combining GLP-1 medication with a tailored nutrition and exercise programme, supported by our multidisciplinary care team of prescribers, health coaches, dietitians, nurses and pharmacists. Our published clinical research demonstrates that our combined approach to weight management and lifestyle change means that our patients are 4x as likely to lose significant weight through their course of treatment with Juniper. Since launching, we’ve grown fast to support millions of patients. In 2024 alone… In the UK we grew from 5,000 to ~30,000 patients , received selective NICE endorsement for our holistic approach to obesity management, and grew our team from 45 to 165. Globally, grew revenue by >120% YoY, while reducing cash burned by 90% YoY and grew our valuation to >$500M USD, with over $100M USD raised from global investors such as BOND, NewView, Blackbird and Airtree - early backers of companies like Canva, Stripe and AirBnb. What’s next? Since reaching over 60,000 patients globally through our weight management program, our goal in 2025 is to extend access to our core treatment program to over 100,000 patients, whilst launching into new conditions, demographics and geographies as we move towards our vision of creating a preventative healthcare ecosystem. We’re going to build the world’s largest international digital healthcare company. This will be really hard to do, but very rewarding and possibly, the adventure of a lifetime with some of the best operators you will ever work with. If that gets you excited, let’s talk.